KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBITDA (2017 - 2025)

Historic EBITDA for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$20.1 million.

  • Biomarin Pharmaceutical's EBITDA fell 12396.73% to -$20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.3 million, marking a year-over-year increase of 2720.6%. This contributed to the annual value of $484.2 million for FY2024, which is 16064.68% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EBITDA of -$20.1 million as of Q3 2025, which was down 12396.73% from $176.8 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EBITDA peaked at $176.8 million during Q2 2025, and registered a low of -$65.9 million during Q4 2021.
  • For the 5-year period, Biomarin Pharmaceutical's EBITDA averaged around $56.9 million, with its median value being $47.0 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 106003.56% in 2023, then plummeted by 12396.73% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's EBITDA stood at -$65.9 million in 2021, then surged by 80.13% to -$13.1 million in 2022, then soared by 308.43% to $27.3 million in 2023, then skyrocketed by 491.69% to $161.4 million in 2024, then plummeted by 112.46% to -$20.1 million in 2025.
  • Its EBITDA stands at -$20.1 million for Q3 2025, versus $176.8 million for Q2 2025 and $143.2 million for Q1 2025.